Drug Profile
MVA p53 vaccine - Tara Immuno-Oncology
Alternative Names: Modified-Vaccinia-Ankara-p53-vaccine; p53-MVA-vaccine; p53MVA vaccine - Tara Immmuno-OncologyLatest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator City of Hope National Medical Center
- Developer City of Hope National Medical Center; National Cancer Institute (USA)
- Class Cancer vaccines; Viral vaccines
- Mechanism of Action P53 gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastrointestinal cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Recurrent, Second-line therapy or greater) in USA (SC)
- 28 May 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (SC)
- 10 May 2018 MVA p53 vaccine is still in phase I trials for Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (SC) (NCT02275039)